IPOGrid
0001620463
IPO filing research
LeonaBio, Inc.
Biological Products, (No Diagnostic Substances) · LONA
follow-on
priced
Nasdaq Capital Market
424B3
LeonaBio, Inc. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: 424B3 on 2026-04-02. Current deal snapshot: exchange Nasdaq Capital Market.
Filing Timeline
SEC EDGAR
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows S-1/A and confirms the priced prospectus.
58,464,567 shares
common · Exchange Nasdaq Capital Market · Ticker LONA · The offering includes shares issuable upon exercise of pre-funded warrants and warrants. · Selling stockholders only · Use of proceeds Proceeds from warrant exercises.
2026-04-02 · 0001193125-26-138620
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows S-1 and confirms the priced prospectus.
Price $0.00 · 5,502,402 shares · Gross proceeds $5,502
5,502,402 Shares of Common Stock · Exchange Nasdaq · Ticker LONA · Pre-funded warrant exercisable at $0.001 per share · Selling stockholders only · Use of proceeds Gross proceeds from warrant exercise · Flags warrants
2026-04-02 · 0001193125-26-138619
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
First tracked pre-IPO filing for this issuer.
LeonaBio, Inc. has received effectiveness for its S-1 registration statement, converting a prior S-3 filing into an S-1. The prospectus outlines the potential offering of 58,464,567 shares of common stock by selling stockholders, including proceeds from warrant exercises. The company, a clinical-stage biopharmaceutical firm, focuses on developing therapies for treatment-resistant metastatic breast cancer and ALS, with lead candidates lasofoxifene and ATH-1105. The filing emphasizes risks associated with its early-stage development and regulatory uncertainties.
2026-04-01 · 9999999995-26-001046
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows DRS and marks the registration effective.
LeonaBio, Inc. filed an S-1 registration statement with the SEC, which became effective on April 1, 2026. The filing confirms the company's eligibility to offer securities to the public, with the same effectiveness date as the previous submission. The current filing includes the same basic details as the prior version, including the company's CIK and SEC file number.
2026-04-01 · 9999999995-26-001045
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior EFFECT filing.
Price $0.00 · 5,502,402 shares · Gross proceeds $5,502
Common Stock · Exchange Nasdaq Capital Market · Ticker LONA · Pre-funded warrant exercisable at $0.001 per share for 5,502,402 shares · Selling stockholders only · Use of proceeds Proceeds from warrant exercise
LeonaBio, Inc. filed a pre-effective amendment (S-1/A) to convert its prior S-3 registration statement into an S-1 form, reflecting its transition from a smaller reporting company to a public offering. The filing relates to the resale of 5,502,402 shares of common stock issuable upon exercise of a pre-funded warrant, with no proceeds going to the company from the selling stockholder's sales. The company, formerly Athira Pharma, Inc., is a clinical-stage biopharmaceutical firm focused on developing therapies for treatment-resistant metastatic breast cancer and ALS.
2026-03-31 · 0001193125-26-134904
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
LeonaBio, Inc. filed a Pre-Effective Amendment No. 1 to convert its S-3 registration statement into an S-1, reflecting a shift in its IPO strategy. The current filing details the offering of 58,464,567 common shares, including shares from pre-funded warrants and warrants, following a December 2025 private placement (PIPE) involving $90 million in proceeds. The company highlights its clinical-stage biopharmaceutical focus on treatments for metastatic breast cancer and ALS, with key drug candidates lasofoxifene and ATH-1105. The filing also outlines terms for warrant exercises tied to clinical trial milestones and regulatory approvals.
2026-03-31 · 0001193125-26-134866
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
The current filing is a Notice of Effectiveness for Athira Pharma, Inc. (CIK: 0001620463) for a Form S-3 registration, effective October 28, 2024. This follows a prior effectiveness notice dated November 24, 2021, for the same company and form, indicating ongoing regulatory compliance for securities offerings.
2024-10-28 · 9999999995-24-003298
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows DRS and confirms the priced prospectus.
Gross proceeds $75,000,000
Common Stock, par value $0.0001 per share · Exchange Nasdaq Global Select Market · Ticker ATHA · Use of proceeds for working capital and other general corporate purposes · Underwriters Cantor Fitzgerald & Co., BTIG, LLC
2023-01-06 · 0000950170-23-000361
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B4 and marks the registration effective.
Athira Pharma, Inc. filed a Form S-3 registration statement for the offering of 4,000,000 shares of common stock at $22.50 per share, with underwriters including Goldman Sachs & Co. LLC, Jefferies, Stifel, and JMP Securities. The company, an emerging growth company, focuses on developing small molecules targeting the HGF/MET pathway for neurodegenerative diseases like Alzheimer's. Its lead candidate, ATH-1017, showed promising Phase 1/2 trial results, including improved P300 latency in Alzheimer's patients, with Phase 2/3 trials ongoing. Proceeds from the offering are expected to fund clinical development and operations.
2021-11-24 · 9999999995-21-004485
424B4
priced
Final prospectus
Final prospectus filed after pricing with final deal terms.
Follows EFFECT and confirms the priced prospectus.
Price $22.50 · 4,000,000 shares · Gross proceeds $90,000,000
Common Stock · Exchange Nasdaq Global Select Market · Ticker ATHA · Over-allotment 600,000 · Use of proceeds Proceeds will be used for general corporate purposes · Underwriters Goldman Sachs & Co. LLC, Jefferies, Stifel
Athira Pharma, Inc. is offering 4,000,000 shares of common stock at $22.50 per share, with underwriters including Goldman Sachs, Jefferies, Stifel, and JMP Securities. The company is a biopharmaceutical firm focused on developing small molecules to treat neurodegenerative diseases, with its lead candidate ATH-1017 in Phase 2/3 trials for Alzheimer's disease. The filing highlights risks related to clinical trial outcomes, regulatory approval, and dependence on a single product candidate.
2021-01-21 · 0001564590-21-001770
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows S-1 and marks the registration effective.
The Notice of Effectiveness indicates that Athira Pharma, Inc.'s S-1 registration statement became effective on January 20, 2021. The company is offering 4,000,000 shares of common stock, with underwriters including Goldman Sachs & Co. LLC, Jefferies, Stifel, and JMP Securities. The filing outlines the proposed offering price, underwriting discounts, and proceeds, while referencing a prospectus containing risk factors and other critical details.
2021-01-20 · 9999999995-21-000203
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS in the pre-IPO sequence.
Price $26.01 · 4,600,000 shares · Gross proceeds $119,646,000
Common · Exchange Nasdaq Global Select Market · Ticker ATHA · Over-allotment 600,000 · Use of proceeds for general corporate purposes · Underwriters Goldman Sachs & Co. LLC, Jefferies, Stifel
Athira Pharma, Inc. is a biopharmaceutical company focused on developing small molecules to restore neuronal health and combat neurodegeneration through HGF/MET signaling. Its lead candidate, ATH-1017, is in Phase 2/3 trials for Alzheimer's disease, showing promising early results in improving cognitive biomarkers. The company aims to leverage its proprietary ATH platform to address CNS and peripheral neurological disorders, with plans for additional trials in Parkinson’s disease dementia and neuropsychiatric indications.
2021-01-19 · 0001564590-21-001397
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
Begins the tracked draft filing sequence after 424B4.
Athira Pharma, Inc. is a biopharmaceutical company focused on developing small molecules to restore neuronal health and combat neurodegeneration. The company's lead candidate, ATH-1017, is a BBB-penetrating HGF/MET activator in clinical trials for Alzheimer's disease (AD), with ongoing Phase 2/3 (LIFT-AD) and Phase 2 (ACT-AD) trials. The filing highlights advancements in clinical data, including improvements in P300 latency and gamma power, while emphasizing risks related to trial outcomes, regulatory approval, and competition. The company remains an emerging growth company with plans to expand its pipeline to other neurological and neuropsychiatric indications.
2021-01-06 · 0000950123-21-000032
424B4
priced
Final prospectus
Final prospectus filed after pricing with final deal terms.
Follows S-1/A and confirms the priced prospectus.
Price $17.00 · 12,000,000 shares · Gross proceeds $204,000,000
Common · Exchange Nasdaq Global Select Market · Ticker ATHA · Over-allotment 1,800,000 · Underwriters Goldman Sachs & Co. LLC, Jefferies, Stifel
Athira Pharma, Inc. is conducting an initial public offering (IPO) of 12,000,000 shares of common stock at $17.00 per share, with proceeds totaling $189.72 million after underwriting discounts. The company, a biopharmaceutical firm focused on neurodegenerative diseases, aims to leverage its ATH platform to develop small molecules targeting HGF/MET signaling for conditions like Alzheimer’s disease. The IPO follows Phase 1 clinical trials for its lead candidate, ATH-1017, which demonstrated tolerability and potential cognitive benefits, with Phase 2/3 trials (LIFT-AD) initiated in 2020.
2020-09-18 · 0001564590-20-043998
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows S-1/A and marks the registration effective.
The filing is a Form S-1 for Athira Pharma, Inc., indicating an effective date of September 17, 2020. The document appears to be a notice of effectiveness with minimal substantive content, lacking detailed financial or operational disclosures. The previous filing (CERT) is not fully accessible for comparison.
2020-09-17 · 9999999995-20-002483
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior EFFECT filing.
Range $15.00 to $17.00 · 10,000,000 shares
Common Stock · Exchange Nasdaq Global Select Market · Ticker ATHA · Over-allotment 1,500,000 · Use of proceeds for general corporate purposes · Underwriters Goldman Sachs & Co. LLC, Jefferies, Stifel
Athira Pharma, Inc. is a biopharmaceutical company developing small molecules to restore neuronal health and address neurodegenerative diseases like Alzheimer's. Its lead candidate, ATH-1017, is in Phase 1/2 trials, showing improved brain function metrics in Alzheimer's patients. The company is conducting Phase 2/3 trials (LIFT-AD) and plans to initiate a Phase 2 trial for Parkinson’s disease dementia. The IPO offers 10 million shares at an estimated $15-$17 per share, with underwriters including Goldman Sachs and Jefferies. The filing amends previous submissions to delay effectiveness and confirms emerging growth company status.
2020-09-17 · 0001564590-20-043758
CERT
inactive
CERT
Pre-IPO filing captured from the SEC submission timeline.
First tracked pre-IPO filing for this issuer.
The current filing for LeonaBio, Inc. is a CERT form dated 2020-09-16, but the text provided is non-readable binary data. The previous filing was an S-1/A for Athira Pharma, Inc., a different company. No actionable information could be extracted due to the corrupted or improperly formatted text.
2020-09-16 · 0001354457-20-000474
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $17.00 · Range $15.00 to $17.00 · 11,500,000 shares · Gross proceeds $195,500,000
Common Stock · Exchange Nasdaq Global Market · Ticker ATHA · Over-allotment 1,500,000 · Use of proceeds for general corporate purposes · Flags emerging_growth_company · Underwriters Goldman Sachs & Co. LLC, Jefferies, Stifel
Athira Pharma, Inc. is a biopharmaceutical company focused on developing small molecules to restore neuronal health and combat neurodegeneration. The company's lead candidate, ATH-1017, is a BBB-penetrating HGF/MET activator in Phase 2/3 trials for Alzheimer's disease (AD), with pivotal data expected by 2022. The IPO aims to raise $195.5 million through the sale of 10 million shares at an estimated price range of $15.00-$17.00 per share, with underwriters including Goldman Sachs, Jefferies, Stifel, and JMP Securities.
2020-09-14 · 0001564590-20-043324
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior 8-A12B filing.
Common Stock
Athira Pharma, Inc. filed an S-1/A amendment to its registration statement, primarily adding exhibits and confirming the registration of common stock for listing on The Nasdaq Stock Market. The filing includes details on underwriting agreements, indemnification provisions, and recent unregistered securities offerings. The amendment does not alter the prospectus content but updates administrative and legal documentation.
2020-09-09 · 0001564590-20-042848
8-A12B
effective
Exchange Act registration
Registration filed to list the securities under the Exchange Act ahead of trading.
Follows S-1 and registers the class of securities for exchange listing.
Athira Pharma, Inc. filed a Form 8-A12B to register its common stock under Section 12(b) of the Securities Exchange Act of 1934, referencing its prior S-1 registration statement. The filing incorporates by reference the capital stock description and prospectus from the S-1, which was initially filed in August 2020. The company aims to list its shares on The Nasdaq Stock Market LLC.
2020-09-09 · 0000950123-20-009608
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS in the pre-IPO sequence.
Gross proceeds $100,000,000
Common Stock · Exchange Nasdaq Global Market · Ticker ATHA · Use of proceeds to fund operations and other general corporate purposes · Underwriters Goldman Sachs & Co. LLC, Jefferies, Stifel
Athira Pharma, Inc. is a biopharmaceutical company focused on developing small molecules to restore neuronal health and combat neurodegeneration. Its lead candidate, ATH-1017, is a BBB-penetrating HGF/MET activator in Phase 1 trials for Alzheimer's disease (AD), showing improved brain function metrics like P300 latency. The company plans Phase 2/3 trials for AD and Phase 2 trials for Parkinson’s disease dementia (PDD), with an IPO aiming to raise up to $100 million. The filing highlights its proprietary ATH platform for targeting CNS and peripheral nervous system disorders.
2020-08-26 · 0001564590-20-041369
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
Athira Pharma, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to raise capital for clinical development and operational expansion. The company is a biopharmaceutical firm focused on developing small molecules to restore neuronal health and address neurodegenerative diseases like Alzheimer's. Its lead candidate, ATH-1017, is in Phase 1 trials for Alzheimer's and is progressing toward pivotal Phase 2/3 trials. The offering is underwritten by Goldman Sachs, Jefferies, Stifel, and JMP Securities, with plans to list on Nasdaq under 'ATHA'. The company emphasizes its novel HGF/MET pathway targeting and highlights risks related to clinical trial outcomes and regulatory approvals.
2020-07-24 · 0000950123-20-007179
Comparable Deals
14 comparable deals
Healthcare & BiotechMicro (<$50M)Last 18 months
Only 0 strict matches; expanded to 14 using nearest neighbors.
Showing top 8 by similarity.
Odyssey Therapeutics, Inc.
ODTX
same SICrecent IPO
Hemab Therapeutics Holdings, Inc.
COAG
same SICrecent IPO
Agomab Therapeutics NV
AGMB
same SICrecent IPO
Eikon Therapeutics, Inc.
EIKN
same SICrecent IPO
Seaport Therapeutics, Inc.
SPTX
same SIC grouprecent IPO
Avalyn Pharma Inc.
AVLN
same SIC grouprecent IPO
First Tracks Biotherapeutics, Inc.
TRAX
same SIC grouprecent IPO
Kailera Therapeutics, Inc.
KLRA
same SIC grouprecent IPO
Recent News
No recent news stored for this issuer.